Update on Functional Inhibitors of Acid Sphingomyelinase (FIASMAs) in SARS-CoV-2 InfectionPerspective Published on 2021-07-182022-10-28 Journal: Pharmaceuticals [Category] COVID-19, [키워드] acid acid sphingomyelinase characterized Controlled clinical trial COVID-19 curative double-blinded drug evaluate functional functional inhibitors of acid sphingomyelinase (FIASMAs) in silico in vitro in vivo inhibitor knowledge Mortality off-label outbreak Randomized SARS-CoV-2 SARS-COV-2 infection sphingomyelinase suggested therapy Treatment [DOI] 10.3390/ph14070691 PMC 바로가기 [Article Type] Perspective
The Investigational Clinical Center: a clinical-supportive and patient-centered trial unit model. Ten years of experience through normal and pandemic times of a large pediatric trial center in ItalyInvestigational Clinical Center: 임상 지원 및 환자 중심 시험 단위 모델. 이탈리아의 대규모 소아 임상 센터에서 정상 및 유행성 시기에 걸친 10년의 경험Letter to the Editor Published on 2021-07-132022-09-10 Journal: Italian Journal of Pediatrics [Category] SARS, 임상, [키워드] activities affected best center children clinical Clinical management Clinical research clinical trial Clinical trial unit clinical trials clinician Complete complexity Compliance conducted COVID-19 pandemic Efficacy and safety engage enrolled evaluated Evidence-based medicine feature Good Good Clinical Practice helping ICC implementation include investigator investigators Italy legal guardian majority management Metrics off-label offer overcome pandemic parent parents Patient pediatric Pediatric clinical research pediatrics pharmacological Practice principal investigator Principal Investigators rare diseases recruitment reported Research Research staff Rome supplementary material Support Treatment Trial Trial implementation Trial management unit [DOI] 10.1186/s13052-021-01099-0 PMC 바로가기 [Article Type] Letter to the Editor
Rituximab in Multiple Sclerosis: Are We Ready for Regulatory Approval?Review Published on 2021-07-062024-09-02 Journal: Frontiers in immunology [Category] 대상포진, [키워드] disease-modifying drugs multiple sclerosis off-label regulatory issue rituximab [DOI] 10.3389/fimmu.2021.661882 PMC 바로가기 [Article Type] Review
Two patients with rituximab associated low gammaglobulin levels and relapsed covid-19 infections treated with convalescent plasma회복기 혈장으로 치료한 낮은 감마글로불린 수치 및 재발된 covid-19 감염과 관련된 리툭시맙을 가진 2명의 환자Case Reports Published on 2021-06-012022-09-12 Journal: Transfusion and apheresis science : official journ [Category] MERS, 진단, [키워드] absence antibody chemo-immunotherapy Clinical improvement convalescent plasma COVID-19 CP infusion disease haematological malignancy Hypogammaglobulinemia Infection limitation lymphoma mandatory Neurological complications neutralising antibody new treatment strategy off-label Patient PCR positive risk rituximab SARS-CoV-2 Symptom therapeutic options therapy treated Two patient Viral load virus [DOI] 10.1016/j.transci.2021.103104 PMC 바로가기 [Article Type] Case Reports
The use of therapeutic plasma exchange as adjunctive therapy in the treatment of coronavirus disease 2019: A critical appraisal of the current evidence코로나바이러스 질병 2019의 치료에서 보조 요법으로 치료적 혈장 교환의 사용: 현재 증거에 대한 비판적 평가Review Published on 2021-06-012022-09-11 Journal: Journal of clinical apheresis [Category] 임상, [키워드] acute respiratory syndrome acute respiratory syndrome coronavirus acute respiratory syndrome coronavirus 2 clinical trial clinical trials controlled trials coronavirus coronavirus disease Coronavirus disease 2019 COVID-19 critical appraisal Evidence include off-label pandemic plasma plasma exchange Randomized controlled trial RCTs SARS-CoV-2 SARS-COV-2 infection severe acute respiratory syndrome Coronavirus Therapeutic plasma exchange therapy TPE Treatment Vaccine development while [DOI] 10.1002/jca.21883 PMC 바로가기 [Article Type] Review
Clinical Management of COVID-19: A Review of Pharmacological Treatment OptionsReview Published on 2021-05-282022-10-28 Journal: Pharmaceuticals [Category] COVID-19, [키워드] administration of corticosteroid antivirals applied approval approved casirivimab/imdevimab Chloroquine clinical clinical experience Clinical management clinical study conducted convalescent plasma COVID-19 COVID-19 pandemic COVID-19 therapeutics curtail disease drug drugs Effect Efficacy Efficacy and safety effort Emergency evaluated Evidence Favipiravir FDA global pandemic global scientific community Google Scholar Hydroxychloroquine immunoglobulins interferons intravenous lack management Molecular biology off-label option outbreak pathophysiology pharmacological agent public health reduce REGN-CoV2 Remdesivir Repurposed drug review risk SARS-CoV-2 Scientific community shown Spread standard treatment subsequent the disease therapeutic therapy tissue plasminogen activator Tocilizumab Treatment umifenovir Vaccine Volume while [DOI] 10.3390/ph14060520 PMC 바로가기 [Article Type] Review
Medication of Hydroxychloroquine, Remdesivir and Convalescent Plasma during the COVID-19 Pandemic in Germany—An Ethical AnalysisArticle Published on 2021-05-262022-10-29 Journal: International Journal of Environmental Research an [Category] COVID-19, SARS, [키워드] Affect Analysis analyzed assist Clinical ethics clinical setting clinical study conditions convalescent plasma COVID-19 COVID-19 pandemic disease outbreak distribution drug early stage Effect Epidemic ethical guideline excluded expand facilitate Germany group groups inclusion criteria maintain Medicine off-label pandemic Patient Perspective pharmaceutical preparations public health reaction reduce Remdesivir Repurposed drug SARS-CoV-2 Treatment use of hydroxychloroquine [DOI] 10.3390/ijerph18115685 PMC 바로가기 [Article Type] Article
Off-label tocilizumab and adjuvant iron chelator effectiveness in a group of severe COVID-19 pneumonia patients: A single center experience중증 COVID-19 폐렴 환자 그룹에서 오프라벨 토실리주맙 및 보조제 철 킬레이터 효과: 단일 센터 경험Observational Study Published on 2021-05-072022-09-12 Journal: Medicine [Category] SARS, 임상, 진단, [키워드] acute respiratory syndrome adjuvant analyzed antibody Better center Chinese Comorbidities Comorbidity consecutive patients contribute Control coronavirus disease Coronavirus-2 corticosteroid therapy COVID-19 Critical Critical case Critically ill CRS Cytokine release syndrome death defined effective Effectiveness Emergency enrolled Evolution female ferritin Glucose had no hospital Hydroxychloroquine IL-6 receptor Invasive mechanical ventilation less male monoclonal Noninvasive ventilation occurred off-label outcome oxygen oxygen saturation Patient Pneumonia prevention rapid increase Romania SARS-CoV-2 SARS-COV-2 infection selected serum serum ferritin level Serum level Severe COVID-19 pneumonia severe pneumonia Side effect single center standard care TCZ Tocilizumab treated younger patients [DOI] 10.1097/MD.0000000000025832 PMC 바로가기 [Article Type] Observational Study
Off-Label Use of COVID-19 Vaccines from Ethical Issues to Medico-Legal Aspects: An Italian PerspectiveArticle Published on 2021-04-232022-10-28 Journal: Vaccines [Category] COVID-19, [키워드] administration approved consequence COVID-19 COVID-19 outbreak COVID-19 vaccine COVID19 disease dose drug Ethics Evolution forensic sciences healthcare worker implication International involved issue Italian lack Moderna National off-label off-label use pandemic Pfizer-BioNTech preventive measure public health recommendation safety of vaccines SARS-CoV-2 tested Treatment vaccination Vaccine vaccine doses vaccine strategies [DOI] 10.3390/vaccines9050423 PMC 바로가기 [Article Type] Article
Leflunomide an immunomodulator with antineoplastic and antiviral potentials but drug-induced liver injury: A comprehensive review항종양 및 항바이러스 잠재력을 갖지만 약물 유발 간 손상을 갖는 레플루노마이드 면역조절제: 포괄적인 검토Review Published on 2021-04-012022-09-11 Journal: International immunopharmacology [Category] SARS, 임상, 치료제, [키워드] affected Anti-inflammatory Antineoplastic Antiviral antiviral activity approved Arthritis Autoimmune benefit Bilirubin Biomarkers catalytic Cell cell growth cellular Combination Compound COVID-19 Cytokines de novo synthesis DHODH drug drug-induced Drug-induced liver injury enzyme event growth hepatic impairment hepatic injury Immunoglobulin immunological immunomodulator Immunosuppression inhibit inhibitors joint destruction leflunomide Leflunomide. liver liver enzyme liver enzymes Liver injury membrane mitochondrial nucleotide nucleotides off-label outcome Pathogenesis pathophysiology Patient Perspective pharmacological precautions proliferation Protective Protein pyrimidine reducing Regulatory Relapsing-Remitting Multiple Sclerosis reported required responsible Rheumatoid safety profile SARS CoV SARS CoV-2 serum Treatment Trial tyrosine with COVID-19 [DOI] 10.1016/j.intimp.2021.107398 PMC 바로가기 [Article Type] Review